ClinicalTrials.gg
RecruitingNCT07326189PHAE-PHCCUpdated Nov 9, 2026

Preoperative Right Hepatic Artery Embolization for Locally Advanced Bismuth IIIb and IV Perihilar Cholangiocarcinoma

An interventional study of Preoperative Right Hepatic Artery Embolization in Cholangiocarcinoma Non-resectable, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 9, 2026Now RecruitingFirst site in China+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Klatskin Tumor with a site in China — 9 open to participants now, 11 under way, 1 of them phase 3. Klatskin Tumor · China.

Planned enrollment
16th of 22
33 · median 61
Started
2026
with 3 others
No phase
10 of 29
3 open now
Primary completion
2028-03
later than 6 of 10 live
Registered
27th of 29
by date
Lead sponsor
4 of 29
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Among the 29 studies in Klatskin Tumor with a site in China, this one is the 16th largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2026, is one of 10 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 27th registered.

Klatskin Tumor

82 studies on the registry are indexed under Klatskin Tumor; 27 are open to participants now.

Browse Klatskin Tumor studies →

Open to participants now

9 of the 29 studies in Klatskin Tumor with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 19 Klatskin Tumor studies recruiting now, 11 (58%) set no upper age limit and 5 (26%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Klatskin Tumor with a site in China, or all of them as a file.
02

Study summary

This is a prospective, multicenter, single-arm study investigating the efficacy and safety of preoperative right hepatic artery embolization (PHAE) followed by surgical resection in patients with locally advanced Bismuth IIIb or IV perihilar cholangiocarcinoma (PHCC) involving the right hepatic artery. The standard treatment for such cases is often considered unresectable due to the high risk of hepatic ischemia after arterial resection without reconstruction. This study proposes a strategy: preoperative embolization of the tumor-involved right hepatic artery to stimulate the development of collateral arterial circulation (e.g., from the right inferior phrenic artery), enabling subsequent radical resection of the right hepatic artery without reconstruction. The primary objective is to evaluate the 1-year overall survival rate. Secondary objectives include surgical conversion rate, R0 resection rate, 1-year/3-year recurrence-free survival, 3-year overall survival rate and safety assessment. A total of 33 participants will be enrolled across multiple centers in China.

Read the detailed description

This study aims to validate a novel surgical strategy for locally advanced Bismuth IIIb or IV perihilar cholangiocarcinoma (PHCC) where the tumor involves the right hepatic artery (RHA), rendering the tumor conventionally unresectable due to the high risk of postoperative right hepatic lobe ischemia if the artery is resected without reconstruction. The intervention involves preoperative selective embolization of the tumor-involved RHA using coils. This procedure is intended to induce the development of collateral arterial supply to the right liver lobe from extrahepatic arteries (e.g., right inferior phrenic, adrenal, intercostal arteries) over a 2-4 week period. Following confirmation of collateral circulation via imaging, patients undergo radical left hepatectomy or left trisectionectomy with en-bloc resection of the involved RHA without arterial reconstruction. The study employs a single-arm design. The primary endpoint is the 1-year overall survival (OS) . The study is designed to detect an improvement to 75%, compared to a historical control rate of 54% observed with chemoimmunotherapy for unresectable disease. Secondary endpoints include surgical conversion rate, R0 resection rate, 1-year/3-year recurrence-free survival (RFS), 3-year OS, and safety profiles (incidence of liver abscess, bile leak, post-hepatectomy liver failure, and other Clavien-Dindo ≥ Grade III complications). The study involves multiple phases: screening/preparation (including biliary drainage and portal vein embolization if needed), the PHAE procedure, radical surgery (2-4 weeks post-PHAE), and a 3-year follow-up period. Statistical analysis will be performed on the intention-to-treat (FAS), per-protocol (PPS), and safety (SS) populations.

03

Conditions studied

  • Cholangiocarcinoma Non-resectable

Browse trials for

Keywords

  • Perihilar cholangiocarcinoma
  • Hepatic artery embolization
  • Vascular invasion
  • Surgical conversion
  • Radical resection
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed .
  • Age 18-80 years.
  • Clinical diagnosis of Bismuth IIIb or IV perihilar cholangiocarcinoma, deemed suitable for radical resection via left hepatectomy or left trisectionectomy.
  • Imaging (CTA/MRA) confirms tumor invasion of the right hepatic artery (RHA) that is assessed as "unable to be safely reconstructed after resection" (e.g., involvement of RHA branches or requiring vascular graft for reconstruction).
  • Portal vein on the side of the future liver remnant is not invaded or is reconstructable.
  • performance status 0-1.
  • score ≤ 7 (Class A or B).
  • Adequate organ function (bone marrow, liver, kidney) as per protocol-defined laboratory values.
  • Expected survival ≥ 12 weeks.

Exclusion criteria

Exclusion Criteria:

  • Evidence of distant (M1).
  • History of other within the past 5 years (except cured basal cell carcinoma or cervical carcinoma in situ).
  • Severe cardiac, pulmonary, renal, or cerebrovascular disease as specified in the protocol (e.g., recent myocardial infarction, severe , chronic renal failure stage ≥ III).
  • Uncontrolled active infection or diabetes.
  • Pregnancy or lactation.
  • Allergy to iodinated contrast media.
  • Postoperative pathology confirms non-cholangiocarcinoma.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Preoperative Right Hepatic Artery Embolization + Surgery

    Participants receive preoperative selective embolization of the tumor-involved right hepatic artery, followed 2-4 weeks later by radical left hepatectomy or left trisectionectomy with resection of the involved artery without reconstruction.

    Procedure: Preoperative Right Hepatic Artery Embolization

Interventions

  • ProcedurePreoperative Right Hepatic Artery Embolization

    Participants receive preoperative selective embolization of the tumor-involved right hepatic artery, followed 2-4 weeks later by radical left hepatectomy or left trisectionectomy with resection of the involved artery without reconstruction.

06

What researchers measure

Primary outcomes

  1. 1-Year Overall Survival

    The proportion of patients alive at 1 year after the radical surgery date. Overall survival is defined as the time from surgery to death from any cause.

    Time frame: 1 year post-surgery

Secondary outcomes

  1. Surgical Conversion Rate

    The proportion of enrolled patients who successfully undergo radical resection.

    Time frame: At the time of surgery

  2. R0 Rate

    The proportion of resected patients achieving microscopically negative cut margins at the axial and radial of bile duct tumor.

    Time frame: At the time of surgery

  3. 1-Year and 3-Year Recurrence-Free Survival Rate

    The proportion of patients alive and free of tumor recurrence at 1 and 3 years after surgery. Recurrence-free survival is defined as the time from surgery to the first documented recurrence or death from any cause.

    Time frame: 1 year and 3 years post-surgery

  4. 3-Year Overall Survival

    The proportion of patients alive at 3 years after the radical surgery date.

    Time frame: 3 years post-surgery

  5. Incidence of Major Complications (Clavien-Dindo ≥ Grade III)

    The proportion of patients experiencing post-procedural (embolization or surgery) complications graded as Clavien-Dindo III or higher within 90 days after surgery.

    Time frame: 90 days post-surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Mizuno T, Ebata T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, Watanabe N, Kamei Y, Nagino M. Combined Vascular Resection for Locally Advanced Perihilar Cholangiocarcinoma. Ann Surg. 2022 Feb 1;275(2):382-390. doi: 10.1097/SLA.0000000000004322. PubMed 32976284 ↗
  • Li B, Li Z, Qiu Z, Qin Y, Gao Q, Ao J, Ma W, Jiang X. Surgical treatment of hilar cholangiocarcinoma: retrospective analysis. BJS Open. 2023 May 5;7(3):zrad024. doi: 10.1093/bjsopen/zrad024. PubMed 37194459 ↗
  • Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klumpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. PubMed 37075781 ↗
  • Kang MJ, Jang JY, Chang J, Shin YC, Lee D, Kim HB, Kim SW. Actual Long-Term Survival Outcome of 403 Consecutive Patients with Hilar Cholangiocarcinoma. World J Surg. 2016 Oct;40(10):2451-9. doi: 10.1007/s00268-016-3551-9. PubMed 27206402 ↗
  • Burris HA 3rd, Okusaka T, Vogel A, Lee MA, Takahashi H, Breder V, Blanc JF, Li J, Bachini M, Zotkiewicz M, Abraham J, Patel N, Wang J, Ali M, Rokutanda N, Cohen G, Oh DY. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024 May;25(5):626-635. doi: 10.1016/S1470-2045(24)00082-2. PubMed 38697156 ↗
  • Benson AB 3rd, D'Angelica MI, Abrams T, Ahmed A, Akce M, Anaya DA, Anders R, Are C, Aye L, Bachini M, Baker M, Binder D, Brown DB, Burgoyne A, Castellanos J, Cloyd J, Cullinan D, Franses J, Glazer ES, Harris W, Iyer R, Jennings L, Kelley RK, Khan S, Levine M, Melstrom L, Palta M, Raman S, Ronnekleiv-Kelly S, Sahai V, Stein S, Stephans K, Thanikachalam K, Turk A, Vauthey JN, Venook AP, Yano M, Yopp A, Zhao K, Schonfeld R, Hochstetler C. Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 Sep;23(9):403-418. doi: 10.6004/jnccn.2025.0042. PubMed 40930144 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Mar 2028, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2025
First posted
Jan 8, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2029
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
1 site added — first site in China
Show site
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University · Guangzhou, China
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Sun Yat-sen Memorial Hospital, Sun Yat-sen University · Guangzhou, China
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07326189
Responsible party
Sponsor
First posted
Jan 8, 2026
Start date
Apr 1, 2026
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Xiangde Shi, Doctor
Contact
sxdsdgsdg@126.com
+86-13826064911
Chao Liu, Doctor
Contact
020-34070840

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion